RT Journal Article
SR Electronic
T1 Genetic inactivation of zinc transporter SLC39A5 improves liver function and hyperglycemia in obesogenic settings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.08.21267440
DO 10.1101/2021.12.08.21267440
A1 Chim, Shek Man
A1 Howell, Kristen
A1 Dronzek, John
A1 Wu, Weizhen
A1 Van Hout, Cristopher
A1 Ferreira, Manuel Allen Revez
A1 Ye, Bin
A1 Li, Alexander
A1 Brydges, Susannah
A1 Arunachalam, Vinayagam
A1 Marcketta, Anthony
A1 Locke, Adam E
A1 Bovijn, Jonas
A1 Verweij, Niek
A1 De, Tanima
A1 Lotta, Luca
A1 Mitnaul, Lyndon
A1 LeBlanc, Michelle G.
A1 ,
A1 ,
A1 Carey, David
A1 Melander, Olle
A1 Shuldiner, Alan
A1 Karalis, Katia
A1 Economides, Aris N.
A1 Nistala, Harikiran
YR 2023
UL http://medrxiv.org/content/early/2023/06/22/2021.12.08.21267440.abstract
AB Recent studies have revealed a role for zinc in insulin secretion and glucose homeostasis. Randomized placebo-controlled zinc supplementation trials have demonstrated improved glycemic traits in patients with type II diabetes (T2D). Moreover, rare loss-of-function variants in the zinc efflux transporter SLC30A8 reduce T2D risk. Despite this accumulated evidence, mechanistic understanding of how zinc influences systemic glucose homeostasis and consequently T2D risk remains unclear. To further explore the relationship between zinc and metabolic traits, we searched the exome database of the Regeneron Genetics Center-Geisinger Health System DiscovEHR cohort for genes that regulate zinc levels and associate with changes in metabolic traits. We then explored our main finding using in vitro and in vivo models. We identified rare loss-of-function (LOF) variants (MAF<1%) in Solute Carrier Family 39, Member 5 (SLC39A5) associated with increased circulating zinc (p=4.9x10-4). Trans-ancestry meta-analysis across four studies exhibited nominal association of SLC39A5 LOF variants with decreased T2D risk. To explore the mechanisms underlying these associations, we generated mice lacking Slc39a5. Slc39a5-/- mice display improved liver function and reduced hyperglycemia when challenged with congenital or diet-induced obesity. These improvements result from elevated hepatic zinc levels and concomitant activation of hepatic AMPK and AKT signaling, in part due to zinc mediated inhibition of hepatic protein phosphatase activity. Furthermore, under conditions of diet-induced non-alcoholic steatohepatitis (NASH), Slc39a5-/- mice display significantly attenuated fibrosis and inflammation. Taken together, these results suggest SLC39A5 as a potential therapeutic target for non-alcoholic fatty liver disease (NAFLD) due to metabolic derangements including T2D.Lay summary Loss of the Zinc transporter SLC39A5 protects from obesity-driven hyperglycemia and liver pathology.Manuscript HighlightsHeterozygous loss-of-function mutations in SLC39A5 associated with elevated circulating zinc levels and nominal reduction in type II diabetes risk in humans.Loss of Slc39a5 results in elevated circulating and hepatic zinc levels in mice.Mice lacking Slc39a5 function are protected against hepatic steatosis and hyperglycemia resulting from diet-induced obesity or leptin-receptor deficiency and display reduced hepatic inflammation and fibrosis resulting from diet-induced NASH.Loss of Slc39a5 function results in hepatic AMPK and AKT activation.SLC39A5 is a potential therapeutic target for fatty liver disease and type II diabetes.Competing Interest StatementS.M.C., K.H., W.W., M.A.R.F, B.Y., A.L., S.B., A.M., A.E.L., J.B., N.V., T.D., L.L., L.M., M.G.L., A.S., K.K., A.N.E., are full-time employees of the Regeneron Genetics Center or Regeneron Pharmaceuticals Inc. and hold stock options/restricted stock as part of compensation.Funding StatementThis work was supported by Regeneron PharmaceuticalsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Program Management Team of Regeneron gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript